The FDA removing the clinical hold on co-development partner CEL-SCI’s Phase III trial in head and neck cancer is encouraging. Ergomed is working with CEL-SCI on the Phase III trial and is eligible to a proportional share of all product revenues until a multiple of investment has been returned. Ergomed currently has four co-development partners which offer potentially attractive returns. We reiterate our positive stance on Ergomed.
15 Aug 2017
N+1 Singer - Ergomed - Clinical hold on CEL-SCI’s Phase III removed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - Clinical hold on CEL-SCI’s Phase III removed
- Published:
15 Aug 2017 -
Author:
Sheena Berry -
Pages:
3
The FDA removing the clinical hold on co-development partner CEL-SCI’s Phase III trial in head and neck cancer is encouraging. Ergomed is working with CEL-SCI on the Phase III trial and is eligible to a proportional share of all product revenues until a multiple of investment has been returned. Ergomed currently has four co-development partners which offer potentially attractive returns. We reiterate our positive stance on Ergomed.